Our Alphabody™ platform has the potential to transform
the drug development landscape

Alphabody™ therapeutics

Complix is developing Alphabodies™, a revolutionary class of biotherapeutics that can access a broad range of well-known but challenging disease targets. Alphabodies represent a major advance over current drug formats, namely small chemicals or biologics, as these classes can only access approximately 20% of all known disease targets.

Alphabodies can access a much larger target universe, including intracellular targets, because their unique scaffold structure allows them to combine the most attractive properties of antibodies and small chemical drugs. It is estimated that there are more than 1000 intracellular disease targets that remain unexplored.

Complix is focusing on the development of Cell Penetrating Alphabodies (CPABs), which are designed to address intracellular targets, particularly protein-protein interactions (PPIs). Intracellular PPIs represent an attractive class of targets because they are implicated in many important disease processes, but are considered largely undruggable by conventional small chemical drug formats.

Recent News

06Jan

Complix Enters into Strategic Collaboration with Merck Inc, worth up to US$ 280 million

0 Comments
Complix Enters into Strategic Collaboration with MSD to Develop Cell-Penetrating Alphabodies to Treat Cancer Complix to receive upfront fees, research... Read More →
14Dec

Complix Advances Novel Biospecific Immunotherapeutic CMX-02 – Enters Agreement with Selexis to Access SUREtechnology Platform™

0 Comments
Hasselt, Belgium, December 14, 2015 – Complix NV, a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies™,... Read More →
28Oct

Complix to Present at CHI’s 7th Annual PEGS Europe Summit, November 5, 2015

0 Comments
Hasselt, October 28, 2015 – Complix, a biopharmaceutical company focused on the discovery and development of Alphabodies™, a novel class... Read More →

Alphabody™ platform

Alphabodies™ are a transformative platform with the capacity to address a vast number of disease targets, many of which are currently “undruggable” by the main classes of existing therapeutics.
Read more

Therapeutic programs

Complix’s drug development is initially focused on cancer and autoimmune disease, therapeutic areas that represent a significant opportunity for new therapeutic interventions based on addressing intracellular targets.
Read more

Partnering

In parallel with its own development activities Complix is keen to work with partners to help deliver the significant potential of its Alphabody™ platform.
Read more

Back to Top